

COMPUGEN LTD
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE
INCOME

(U.S. dollars in thousands, except for share and per-share amounts)

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2013	2012	2013	2012
	<u>Unaudited</u>	<u>Unaudited</u>	<u>Unaudited</u>	<u>Unaudited</u>
Revenues	1,590	108	1,774	108
Cost of revenues	<u>1,465</u>	<u>33</u>	<u>1,699</u>	<u>33</u>
Gross profit	<u>125</u>	<u>75</u>	<u>75</u>	<u>75</u>
Operating expenses				
Research and development expenses, net	2,842	2,787	9,018	6,834
Marketing and business development expenses	415	147	767	498
General and administrative expenses	<u>1,270</u>	<u>765</u>	<u>3,375</u>	<u>2,444</u>
Total operating expenses *	<u>4,527</u>	<u>3,699</u>	<u>13,160</u>	<u>9,776</u>
Operating loss	(4,402)	(3,624)	(13,085)	(9,701)
Financing income (loss), net **	<u>(185)</u>	<u>114</u>	<u>2,085</u>	<u>1,446</u>
Net loss before taxes	(4,587)	(3,510)	(11,000)	(8,255)
Taxes on income	<u>155</u>	<u>-</u>	<u>155</u>	<u>-</u>
Net loss	<u>(4,742)</u>	<u>(3,510)</u>	<u>(11,155)</u>	<u>(8,255)</u>
Basic net loss per ordinary share	(0.12)	(0.10)	(0.29)	(0.23)
Weighted average number of Ordinary shares used in computing basic net loss per share	39,145,119	35,991,398	38,217,843	35,750,276
Diluted net loss per ordinary share	(0.12)	(0.10)	(0.29)	(0.30)
Weighted average number of Ordinary shares used in computing diluted net loss per share	39,145,119	36,797,405	38,217,843	36,406,301

* Includes non-cash stock based compensation.

** Includes non-cash expenses related to the Baize research and development funding arrangements.

COMPUGEN LTD.
CONDENSED CONSOLIDATED BALANCE SHEETS DATA
(U.S. dollars, in thousands)

	September 30,	December 31,
	<u>2013</u>	<u>2012</u>
	<u>Unaudited</u>	<u>Audited</u>
ASSETS		
Current assets		
Cash, cash equivalents and short-term bank deposits	\$ 43,837	\$ 19,589
Restricted cash	101	96
Investment in Evogene	3,985	5,196
Other accounts receivable and prepaid expenses	1,917	690
Receivables on account of shares	<u>2,011</u>	<u>-</u>
Total current assets	<u>51,851</u>	<u>25,571</u>
Non-current investments		
Severance pay fund	<u>2,007</u>	<u>1,728</u>
Total non-current investments	<u>2,007</u>	<u>1,728</u>
Long-term prepaid expenses	<u>185</u>	<u>360</u>
Deferred tax asset	<u>201</u>	<u>-</u>
Property and equipment, net	<u>1,143</u>	<u>1,250</u>
Total assets	<u>\$ 55,387</u>	<u>\$ 28,909</u>
LIABILITIES AND SHAREHOLDERS' EQUITY		
Current liabilities		
Other accounts payable, accrued expenses and trade payables	\$ 3,425	\$ 1,384
Deferred revenue	<u>5,781</u>	<u>-</u>
Total current liabilities	<u>9,206</u>	<u>1,384</u>
Long-term liabilities		
Research and development funding arrangements	14,102	7,872
Deferred revenue	2,720	-
Accrued severance pay	<u>2,329</u>	<u>1,981</u>
Total long-term liabilities	<u>19,151</u>	<u>9,853</u>
Total shareholders' equity	<u>27,030</u>	<u>17,672</u>
Total liabilities and shareholders' equity	<u>\$ 55,387</u>	<u>\$ 28,909</u>